Imugene Limited received a grant for Oncolytic Virotherapy CF33

Imugene Limited (ASX: IMU) announced that it has received a Grant from the Chinese Patent Office for its oncolytic virotherapy CF33. The company had earlier received grants in Japan and South Korea. The granted claims protect the company’s composition method and use of its licensed oncolytic virotherapy CF33, including VAXINIA and CHECKvacc, until 2037. CF33 is a chimeric vaccinia poxvirus that selectively kills tumor cells and activates the immune system against cancer cells, potentially improving clinical response and survival.

The patent titled "CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF" protects Imugene's technology invented by Professor Yuman Fong, Chair of Sangiacomo Family Chair in Surgical Oncology at City of Hope, who is a noted expert in the oncolytic virus field. Receiving patent grants for the CF33 family of oncolytic viruses is a significant milestone that marks a crucial step forward, particularly given that China, Japan, and South Korea are the largest healthcare markets in Asia.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com